To describe the association between pregnancy associated plasma protein A (PAPP-A), alphafetoprotein (AFP) and adverse perinatal outcome.
1
Recent evidence indicates that the activity of the IGF system may be important in very early human pregnancy. A number of studies have related maternal circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a trophoblast derived protease for IGF binding proteins 4 and 5, to eventual perinatal outcome. These studies have shown that low levels of PAPP-A are associated with increased risks of intrauterine growth restriction, preterm birth, and stillbirth. [2] [3] [4] These associations are evident even when confined to samples obtained in the first 10 weeks postconception. 5, 6 Consistent with this, mice that are null mutant for the gene encoding PAPP-A have severe early onset intrauterine growth restriction. 7 It has been appreciated for many years that, in the absence of congenital abnormality, high maternal serum levels of alpha-fetoprotein (AFP) in the second trimester of pregnancy are associated with an increased risk of adverse perinatal outcome. 8 AFP is the major fetal oncotic protein and, when the fetus is structurally normal, high maternal circulating levels are thought to reflect a defect in placentation. It is not yet known, however, whether the placental defect associated with increased placental permeability to AFP is related to the activity of the IGF system. The aim of this study was to describe the relationship between low PAPP-A, high AFP, and intrauterine growth restriction, preterm birth, and stillbirth.
MATERIALS AND METHODS
We used data from the Combined Ultrasound and Biochemical Screening 9 study, a prospective, noninterventional, multicenter study of screening for Down syndrome. The study evaluated the use of ultrasound measurement of fetal nuchal translucency in combination with analysis of maternal serum PAPP-A and the free ␤ subunit of human chorionic gonadotrophin as a first trimester screening test for Down syndrome in a routine prenatal clinic setting. Information leaflets about the study were sent to women with the notification of their first appointment for prenatal care. Those women whose first visit was at 14 weeks of gestation or less were invited to participate, and those who agreed signed a consent form. Participation in the study involved measuring nuchal translucency at the time of the first ultrasound and obtaining additional blood at the time of phlebotomy for routine prenatal investigations. No results were reported to either the obstetrician or patient, and prenatal care was not modified in any way by participation in the study. Ethical approval was obtained from the Scottish Multicenter Research Ethics Committee. Fifteen Scottish maternity units participated in the Combined Ultrasound and Biochemical Screening study during a 2-year period between 1997 and 1999, and 98.6% of records came from births in 11 of the hospitals. Ninety-eight percent of the births occurred between May 1998 and July 2000. Births to women recruited to the study constituted 28.6% of all births in the 11 hospitals during that period.
Maternal levels of PAPP-A were measured from blood obtained at the time of the first prenatal visit (10 -14 weeks) as part of the Combined Ultrasound and Biochemical Screening study. Maternal levels of AFP were determined by two methods. First, we performed record linkage of the Combined Ultrasound and Biochemical Screening database to the database of the laboratory information management system for the prenatal screening program of the West of Scotland Regional Genetics Service of the Institute of Medical Genetics in Glasgow. Second, part of the cohort was followed up by manual retrieval of the case notes, and the AFP level was obtained directly from the case record. PAPP-A was assayed between 10 and 14 weeks gestation and AFP between 15 and 21 weeks. The outcome of the pregnancy was ascertained by linkage of the Combined Ultrasound and Biochemical Screening database to the Scottish Morbidity Record 10 and the Scottish Stillbirth and Infant Death Enquiry. 11 The Scottish Morbidity Record is a national register of perinatal outcome data, 10 and the Scottish Stillbirth and Infant Death Enquiry is a national register that routinely classifies all perinatal deaths in Scotland. 11 The Scottish Stillbirth and Infant Death Enquiry has data on 100% of registered stillbirths, 11 and the Scottish Morbidity Record contains data on 99.6% of certified births. 10 The record linkage and the details of the other data sources and definitions are described in detail elsewhere. 6, 12 The study cohort (N ϭ 8,483) for the current analysis was defined by women who participated in the Combined Ultrasound and Biochemical Screening study, who had both PAPP-A and AFP results documented, and who could be linked to the Scottish Morbidity Record where singleton birth occurred at or after 24 weeks gestation.
Small for gestational age (SGA) was defined on the basis of centiles derived from the cohort, and preterm birth was defined as delivery before 37 completed weeks of gestation. Socioeconomic status was estimated on the basis of the postal code of the mother's residence, according to Carstairs socioeconomic-deprivation categories (based on 1991 Census data on car ownership, employment status, number of occupants per household room, and social class within postal-code sectors of residence that contain, on average, about 1,600 residents). 13 Higher scores indicate residence within areas of greater deprivation.
Maternal serum levels of PAPP-A and AFP were expressed as multiples of the median (MoM) for gestational age, as is conventional for biochemical indices in pregnancy that vary with week of gestation. Because PAPP-A and AFP levels vary inversely with maternal weight, MoM were corrected for maternal weight using reciprocal-linear regression. This is widely employed in prenatal screening and is described in detail elsewhere.
14 Separate PAPP-A MoM were estimated for smokers, because PAPP-A is reduced by 15% among smokers. 9 Low PAPP-A was defined as the lowest 5% of values for gestational age (Յ 0.4 MoM), and high AFP was defined as the top 5% of values for gestational age (Ն 1.7 MoM). Univariate comparison of continuous variables was performed using the Mann-Whitney U test and categorical data using the Fisher exact test. All P values were 2-tailed. Statistical significance was assumed at P Ͻ .05. Multivariate analysis was performed using logistic regression. 15 Cases with missing data on covariates were dropped from the multivariate analysis. Interaction terms were assessed using the likelihood ratio test. All statistical analyses were performed using the Stata 8 software package (Stata Corporation, College Station, TX).
RESULTS
The linked database contained 11,729 records of women who had a PAPP-A documented and had a Scottish Morbidity Record. Three (0.03%) records were excluded because the gestational age at delivery was less than 24 weeks, 2 (0.02%) because of missing data on sex of the baby, and 3 (0.03%) because of missing data on weight. Of the remaining 11,721 births, 8,483 (72.4%) had an AFP level recorded, and these women constituted the study cohort. The characteristics of the study cohort are described in Table 1 . Low PAPP-A was associated with an increased risk of delivering an SGA infant, preterm birth, and stillbirth (Table 2 ). An elevated AFP was associated with an increased risk of preterm birth and stillbirth (Table 2 ). Women with a low level of PAPP-A were not at increased risk of having a high AFP (odds ratio 1.3, 95% confidence interval [CI] 0.9 -1.9). Adjusting each factor for the other was without material effect on the strength of associations (Table 3) . Similarly adjusting for maternal characteristics had a minimal effect on the strength of the associations (Table 3) .
We then studied outcome for high AFP and low PAPP-A, either singly or in combination, with reference to women with normal values of both AFP and PAPP-A (this is a different referent category from Table 3 and thus odds ratios differ slightly from Table  3 ). The odds ratio for delivering a small for gestational age infant for women with a high AFP was 0.9 (95% CI 0.5-1.6), for women with a low PAPP-A was 2.8 (95% CI 2.0 -4.0), and for women with both a high AFP and a low PAPP-A was 8.5 (95% CI 3.6 -20.0). The odds ratio for delivering preterm for women with a high AFP was 1.8 (95% CI 1.3-2.7), for women with a low PAPP-A was 1.9 (95% CI 1.3-2.7), and for women with both a low PAPP-A and a high AFP was 9.9 (95% CI 4.4 -22.0). The odds ratio for antepartum stillbirth for women with a high AFP was 2.5 (95% CI 0.6 -10.9), for women with a low PAPP-A was 2.2 (95% CI 0.5-9.7), and for women with both a low PAPP-A and a high AFP was 36.7 (95% CI 8.0 -167.6). Receiver operating characteristic curve analysis of PAPP-A, AFP, and maternal characteristics in predicting adverse outcome is shown in Table 4 . There were statistically significant positive interactions ( Fig. 1 ) between PAPP-A and AFP in the risk of delivering a SGA infant (P ϭ .03), preterm birth (P ϭ .04) and a trend toward a positive interaction in the risk of stillbirth (P ϭ .14). Of the women with the combination of a low PAPP-A and high AFP, 32.1% (95% CI 15.9 -52.4) delivered a low birth weight infant. 
DISCUSSION
A number of lines of evidence support an important role for the activity of the IGF system in the first trimester of pregnancy in determining perinatal outcome. Insulin-like growth factor II is highly expressed in trophoblast and is likely to control both maternal PAPP-A, pregnancy-associated plasma protein A; AFP, alpha-fetoprotein; OR, odds ratio; CI, confidence interval; SGA, small for gestational age. Data are expressed as n (%) and OR (95% CI). The difference in the number of births in the top fifth percentile of AFP (n ϭ 412) and the lowest fifth percentile of PAPPA (n ϭ 457) is due to their being ties in the data set. In an event of a tie, where percentiles are the same, they are grouped into the lower percentile category. As a result, the lowest fifth percentile of PAPPA has 5.4% births (greater than 5%) and the highest fifth percentile of AFP has 4.9% births (less than 5%). PAPP-A, pregnancy associated plasma protein A; AFP, alpha-fetoprotein; OR, odds ratio; CI, confidence interval; SGA, small for gestational age. Values are OR (95% CI). Odds ratios are for a low PAPP-A referent to a normal PAPP-A (irrespective of AFP) and for a high AFP referent to a normal AFP (irrespective of PAPP-A). * Maternal characteristics included in the model were age, height, body mass index, deprivation category, marital status, smoking status, ethnicity, parity, and hospital where the birth took place. † Number of events too small for estimation using full multivariate model. and placental tissues at the site of implantation. 1 Low maternal levels of PAPP-A, a trophoblast-derived protease for IGF binding proteins-4 and IGF binding proteins-5, 16 are associated with increased risks of intrauterine growth restriction, preterm birth, and stillbirth. [2] [3] [4] Mice which are null mutant for the PAPP-A gene are also at increased risk of early-onset intrauterine growth restriction, 7 which supports a causal role for PAPP-A in determining outcome.
Many previous studies had shown that high maternal levels of the fetal oncotic protein, AFP, were associated with an increased risk of complications in later pregnancy. 8 It was not apparent, however, whether PAPP-A was a marker for the same placental defect that leads to high rates of placental transfer of AFP. The present study had 3 major findings. First, we show that women who had low levels of PAPP-A were not more likely to have elevated levels of AFP in the second trimester of pregnancy. This suggests that the pathophysiologic process leading to high placental transfer rates of AFP is not related to the IGF system, insofar as it can be assessed by circulating levels of PAPP-A. Second, we show that adjustment for the levels of PAPP-A had a minimal effect on the strength of association between AFP and adverse outcome, and vice versa. If low levels of PAPP-A and high levels of AFP were markers of the same underlying defect in placental function, it would have been anticipated that adjustment of 1 factor for the level of the other would have resulted in a weaker association. The lack of an effect of such adjustment suggests that low PAPP-A and high AFP are consequences of distinct processes and that extreme levels indicate different aspects of placental dysfunction. Finally, we show the combination of a low PAPP-A and a high AFP was synergistically associated with adverse outcome. This indicates that the consequences of the 2 underlying processes must interact. These clinical observations indicate complexity in the placental determinants of adverse perinatal outcome and underline the importance of understanding the biology of trophoblast function in early pregnancy as a determinant of complications in late pregnancy.
The combination of low PAPP-A and high AFP is not likely to be clinically useful as a means of population-based screening to identify women at high risk of pregnancy complications. Relatively few women will have the combination of a low PAPP-A and a high AFP. Consequently, the sensitivity of this test will be low and would not, in itself, justify populationbased screening for these outcomes. However, maternal serum levels of PAPP-A and AFP are used in Down syndrome screening, and inevitably, this process will identify women who have the combination of both a low PAPP-A and a high AFP. Women with this combination had a 32.1% risk of delivering a low Fig. 1 . Odds ratios for combinations of low pregnancyassociated plasma protein A and high alpha-fetoprotein in predicting delivery of a small for gestational age infant (A), preterm delivery (B), and stillbirth (C). The odds ratios for interaction terms between a low pregnancy-associated plasma protein A and a high alpha-fetoprotein were 3.4 (95% CI 1.2-9.8, P ϭ .03) for small for gestational age, 2.8 (95% CI 1.1-7.2, P ϭ .04) for preterm birth and 6.6 (95% CI 0.5-78.9, P ϭ .14) for stillbirth. All odds ratios are referent to women with both a normal pregnancy-associated plasma protein A and a normal alpha-fetoprotein. SGA, small for gestational age; AFP, alpha-fetoprotein; PAPPA, pregnancyassociated plasma protein A. 
